The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone

Broad-spectrum antibiotics can kill both pathogens and gut microbiota. Reducing exposure to excess intestinal antibiotics could theoretically protect gut microbiota homeostasis. Recently, engineered charcoals, gel microparticles, and resin beads have demonstrated efficacy in intestinal antibiotic adsorption in animal studies. We report the first in vitro study evaluating human fecal antibiotic adsorption efficacy of conventional activated charcoal (AC). We collected fecal samples from eight patients who received intravenous (IV) ceftriaxone after admission to King Chulalongkorn Memorial Hospital, Thailand, during January–March 2020. Fecal ceftriaxone was measured by indirect competitive enzyme-linked immunoassays. Three different doses of AC were mixed with fecal samples under a specified protocol. The geometric mean reduction in fecal ceftriaxone concentration when mixed with AC 30 mg/g feces was 0.53 (95% CI 0.33–0.85, p-value < 0.001), meaning 47% adsorption efficacy. Increased adsorption was found with higher doses, 71% and 87% for AC 150 and 500 mg/g feces, respectively. In conclusion, the usual food-poisoning-care dose of conventional AC, 30 mg/g feces, demonstrated dose-dependent and significant fecal ceftriaxone adsorption. Conventional oral AC might be a pragmatic and inexpensive option for the protection of gut microbiota in patients receiving IV ceftriaxone. However, in vivo studies and microbiome analysis are needed for further evidence.

[1]  A. Kishimura,et al.  Specific adsorption of a β-lactam antibiotic in vivo by an anion-exchange resin for protection of the intestinal microbiota. , 2021, Biomaterials science.

[2]  A. Kishimura,et al.  Protection of gut microbiome from antibiotics: development of a vancomycin-specific adsorbent with high adsorption capacity , 2020, Bioscience of microbiota, food and health.

[3]  R. Carman,et al.  Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection. , 2018, Anaerobe.

[4]  E. Le Chatelier,et al.  Protection of the Human Gut Microbiome From Antibiotics , 2017, bioRxiv.

[5]  Muthanna J. Ahmed,et al.  Adsorption of quinolone, tetracycline, and penicillin antibiotics from aqueous solution using activated carbons: Review. , 2017, Environmental toxicology and pharmacology.

[6]  S. Tzipori,et al.  Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. , 2016, Anaerobe.

[7]  M. Henn,et al.  A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. , 2016, The Journal of infectious diseases.

[8]  Frédéric Leroy,et al.  Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut , 2016, Front. Microbiol..

[9]  N. Safdar,et al.  Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. , 2016, American journal of infection control.

[10]  O. Mathieu,et al.  Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  James Kinross,et al.  The gut microbiota and host health: a new clinical frontier , 2015, Gut.

[12]  J. de Gunzburg,et al.  Oral DAV131, a Charcoal-Based Adsorbent, Inhibits Intestinal Colonization by β-Lactam-Resistant Klebsiella pneumoniae in Cefotaxime-Treated Mice , 2013, Antimicrobial Agents and Chemotherapy.

[13]  Rafael Bargiela,et al.  Gut microbiota disturbance during antibiotic therapy: a multi-omic approach , 2012, Gut.

[14]  H. Masur,et al.  Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit , 2012, Critical care medicine.

[15]  N. Secher,et al.  Pulmonary artery and intestinal temperatures during heat stress and cooling. , 2012, Medicine and science in sports and exercise.

[16]  T. Albertson,et al.  Gastrointestinal decontamination in the acutely poisoned patient , 2011, International journal of emergency medicine.

[17]  T. Arakawa,et al.  Highly efficient renaturation of β‐lactamase isolated from moderately halophilic bacteria , 2004, FEBS letters.

[18]  J. Bartlett,et al.  A NTIBIOTIC -A SSOCIATED D IARRHEA , 2002 .

[19]  R. Weinstein,et al.  The Role of Colonization in the Pathogenesis of Nosocomial Infections , 1996, Infection Control &#x0026; Hospital Epidemiology.

[20]  J. Peris,et al.  Renal and nonrenal clearances of ceftriaxone at the steady-state and its relation to plasma protein binding , 1995 .

[21]  T. Albertson,et al.  Activated charcoal--past, present and future. , 1986, The Western journal of medicine.

[22]  I. Patel,et al.  Pharmacokinetics of ceftriaxone in humans , 1981, Antimicrobial Agents and Chemotherapy.

[23]  S. Phillips,et al.  Capacity of the human colon to absorb fluid , 1978 .

[24]  H. Knothe,et al.  Impact of Cefotaxime and Ceftriaxone on the Bowel and Vaginal Flora after Single-Dose Prophylaxis in Vaginal Hysterectomy , 2012, Drugs.

[25]  R. Weinstein,et al.  The role of colonization in the pathogenesis of nosocomial infections. , 1996, Infection control and hospital epidemiology.

[26]  S. Phillips,et al.  Capacity of the human colon to absorb fluid. , 1978, Gastroenterology.